EAM
AGRX

EverPoint Asset Management’s Agile Therapeutics AGRX Stock Holding History

EverPoint Asset Management’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$1.14M Buy
+100
New +$1.4M 0.02% 365

Other funds holding AGRX

PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

EverPoint Asset Management's AGRX Position: Q4 2016 in Review

EverPoint Asset Management opened a new position in Agile Therapeutics (AGRX) in Q4 2016: 100 shares worth $1.14M. The stake represents 0.02% of the portfolio and ranks #365 among its holdings.

62 funds tracked by Wall St. Rank hold AGRX as of Q4 2016.

  • EverPoint Asset Management held 100 shares of Agile Therapeutics worth $1.14M as of Q4 2016.
  • Agile Therapeutics was a new EverPoint Asset Management position in Q4 2016.
  • Agile Therapeutics made up 0.02% of EverPoint Asset Management's portfolio in Q4 2016, its #365 holding.
  • 62 funds tracked by Wall St. Rank held Agile Therapeutics as of Q4 2016.

Based on EverPoint Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.